{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:41:47Z","timestamp":1788406907401,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["72110"],"award-info":[{"award-number":["72110"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013898","name":"Milli E\u011fitim Bakanli\u011fi","doi-asserted-by":"publisher","award":["2018 - YLSY"],"award-info":[{"award-number":["2018 - YLSY"]}],"id":[{"id":"10.13039\/501100013898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004270","name":"Royal Institute of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004270","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite numerous clinical trials and decades of endeavour, there is still no effective cure for Alzheimer's disease. Computational drug repositioning approaches may be employed for the development of new treatment strategies for Alzheimer\u2019s patients since an extensive amount of omics data has been generated during pre-clinical and clinical studies. However, targeting the most critical pathophysiological mechanisms and determining drugs with proper pharmacodynamics and good efficacy are equally crucial in drug repurposing and often imbalanced in Alzheimer\u2019s studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Here, we investigated central co-expressed genes upregulated in Alzheimer\u2019s disease to determine a proper therapeutic target. We backed our reasoning by checking the target gene\u2019s estimated non-essentiality for survival in multiple human tissues. We screened transcriptome profiles of various human cell lines perturbed by drug induction (for 6798 compounds) and gene knockout using data available in the Connectivity Map database. Then, we applied a profile-based drug repositioning approach to discover drugs targeting the target gene based on the correlations between these transcriptome profiles. We evaluated the bioavailability, functional enrichment profiles and drug-protein interactions of these repurposed agents and evidenced their cellular viability and efficacy in glial cell culture by experimental assays and Western blotting. Finally, we evaluated their pharmacokinetics to anticipate to which degree their efficacy can be improved.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified glutaminase as a promising drug target. Glutaminase overexpression may fuel the glutamate excitotoxicity in neurons, leading to mitochondrial dysfunction and other neurodegeneration hallmark processes. The computational drug repurposing revealed eight drugs: mitoxantrone, bortezomib, parbendazole, crizotinib, withaferin-a, SA-25547 and two unstudied compounds. We demonstrated that the proposed drugs could effectively suppress glutaminase and reduce glutamate production in the diseased brain through multiple neurodegeneration-associated mechanisms, including cytoskeleton and proteostasis. We also estimated the human blood\u2013brain barrier permeability of parbendazole and SA-25547 using the SwissADME tool.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study method effectively identified an Alzheimer\u2019s disease marker and compounds targeting the marker and interconnected biological processes by use of multiple computational approaches. Our results highlight the importance of synaptic glutamate signalling in Alzheimer\u2019s disease progression. We suggest repurposable drugs (like parbendazole) with well-evidenced activities that we linked to glutamate synthesis hereby and novel molecules (SA-25547) with estimated mechanisms for the treatment of Alzheimer\u2019s patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04192-6","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T05:01:55Z","timestamp":1684558915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer\u2019s disease patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Abdulahad","family":"Bayraktar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonghee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Turkez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Shoaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4254-6090","authenticated-orcid":false,"given":"Adil","family":"Mardinoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"4192_CR1","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.3390\/app10155076","volume":"10","author":"Y Ko","year":"2020","unstructured":"Ko Y. Computational drug repositioning: current progress and challenges. Appl Sci. 2020;10:5076.","journal-title":"Appl Sci"},{"key":"4192_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13273","author":"JP Jourdan","year":"2020","unstructured":"Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020. https:\/\/doi.org\/10.1111\/jphp.13273.","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"4192_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/jnc.15224","volume":"156","author":"KN Hascup","year":"2021","unstructured":"Hascup KN, Findley CA, Britz J, Esperant-Hilaire N, Broderick SO, Delfino K, et al. Riluzole attenuates glutamatergic tone and cognitive decline in A\u03b2PP\/PS1 mice. J Neurochem. 2021;156(4):513\u201323. https:\/\/doi.org\/10.1111\/jnc.15224.","journal-title":"J Neurochem"},{"issue":"12","key":"4192_CR4","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1093\/brain\/awab222","volume":"144","author":"DC Matthews","year":"2021","unstructured":"Matthews DC, Mao X, Dowd K, Tsakanikas D, Jiang CS, Meuser C, et al. Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer\u2019s disease. Brain. 2021;144(12):3742\u201355.","journal-title":"Brain"},{"issue":"11","key":"4192_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","volume":"78","author":"K Vossel","year":"2021","unstructured":"Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, et al. Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 2021;78(11):1345\u201354.","journal-title":"JAMA Neurol"},{"key":"4192_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113945","author":"K Mullane","year":"2020","unstructured":"Mullane K, Williams M. Alzheimer\u2019s disease beyond amyloid: can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery? Biochem Pharmacol. 2020. https:\/\/doi.org\/10.1016\/j.bcp.2020.113945.","journal-title":"Biochem Pharmacol"},{"key":"4192_CR7","doi-asserted-by":"crossref","unstructured":"Clough E, Barrett T. The Gene Expression Omnibus database. In: Methods in Molecular Biology [Internet]. NIH Public Access; 2016 [cited 2022 Mar 28]. p. 93\u2013110. Available from: \/pmc\/articles\/PMC4944384\/","DOI":"10.1007\/978-1-4939-3578-9_5"},{"issue":"D1","key":"4192_CR8","doi-asserted-by":"publisher","first-page":"D1060","DOI":"10.1093\/nar\/gkr901","volume":"40","author":"AC Culhane","year":"2012","unstructured":"Culhane AC, Schr\u00f6der MS, Sultana R, Picard SC, Martinelli EN, Kelly C, et al. GeneSigDB: a manually curated database and resource for analysis of gene expression signatures. Nucleic Acids Res. 2012;40(D1):D1060\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"4192_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437\u201352.","journal-title":"Cell"},{"issue":"1","key":"4192_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1039\/C8MO00214B","volume":"15","author":"Z Cheng","year":"2019","unstructured":"Cheng Z, Wen Y, Liang B, Chen S, Liu Y, Wang Z, et al. Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD. Mol Omi. 2019;15(1):50\u20138.","journal-title":"Mol Omi"},{"key":"4192_CR11","doi-asserted-by":"publisher","first-page":"D187","DOI":"10.1093\/nar\/gkj161","volume":"34","author":"CH Wu","year":"2006","unstructured":"Wu CH, Apweiler R, Bairoch A, Natale DA, Barker WC, Boeckmann B, et al. The universal protein resource (UniProt): an expanding universe of protein information. Nucleic Acids Res. 2006;34:D187\u201391.","journal-title":"Nucleic Acids Res"},{"key":"4192_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9089-4_6","volume-title":"Leveraging big data to transform drug discovery","author":"BS Glicksberg","year":"2019","unstructured":"Glicksberg BS, Li L, Chen R, Dudley J, Chen B. Leveraging big data to transform drug discovery. Bethesda: NIH Public Access; 2019."},{"key":"4192_CR13","doi-asserted-by":"publisher","first-page":"103963","DOI":"10.1016\/j.ebiom.2022.103963","volume":"78","author":"X Li","year":"2022","unstructured":"Li X, Shong K, Kim W, Yuan M, Yang H, Sato Y, et al. Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach. EBioMedicine. 2022;78:103963.","journal-title":"EBioMedicine"},{"issue":"6","key":"4192_CR14","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3390\/cancers14061573","volume":"14","author":"M Yuan","year":"2022","unstructured":"Yuan M, Shong K, Li X, Ashraf S, Shi M, Kim W, et al. A gene co-expression network-based drug repositioning approach identifies candidates for treatment of hepatocellular carcinoma. Cancers. 2022;14(6):1573.","journal-title":"Cancers"},{"key":"4192_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262751","author":"R Bonnet","year":"2022","unstructured":"Bonnet R, Mariault L, Peyron JF. Identification of potentially anti-COVID-19 active drugs using the connectivity MAP. PLoS ONE. 2022. https:\/\/doi.org\/10.1371\/journal.pone.0262751.","journal-title":"PLoS ONE"},{"key":"4192_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2016.10.003","volume":"15","author":"AJ Nevado-Holgado","year":"2017","unstructured":"Nevado-Holgado AJ, Lovestone S. Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer\u2019s disease: a bioinformatics approach. Comput Struct Biotechnol J. 2017;15:1\u20137. https:\/\/doi.org\/10.1016\/j.csbj.2016.10.003.","journal-title":"Comput Struct Biotechnol J"},{"key":"4192_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111556","author":"A Bayraktar","year":"2021","unstructured":"Bayraktar A, Lam S, Altay O, Li X, Yuan M, Zhang C, et al. Revealing the molecular mechanisms of Alzheimer\u2019s disease based on network analysis. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222111556.","journal-title":"Int J Mol Sci"},{"key":"4192_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104214","author":"C Zhang","year":"2022","unstructured":"Zhang C, Shi M, Kim W, Arif M, Klevstig M, Li X, et al. Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning. EBioMedicine. 2022. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104214.","journal-title":"EBioMedicine"},{"issue":"7","key":"4192_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1177\/1533317513500838","volume":"28","author":"F Chen","year":"2013","unstructured":"Chen F, Guan Q, Nie ZY, Jin LJ. Gene expression profile and functional analysis of Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen. 2013;28(7):693\u2013701.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"1","key":"4192_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0254-8","volume":"13","author":"S Rangaraju","year":"2018","unstructured":"Rangaraju S, Dammer EB, Raza SA, Rathakrishnan P, Xiao H, Gao T, et al. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer\u2019s disease. Mol Neurodegener. 2018;13(1):1\u201325. https:\/\/doi.org\/10.1186\/s13024-018-0254-8.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"4192_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-019-0555-x","volume":"9","author":"G Williams","year":"2019","unstructured":"Williams G, Gatt A, Clarke E, Corcoran J, Doherty P, Chambers D, et al. Drug repurposing for Alzheimer\u2019s disease based on transcriptional profiling of human iPSC-derived cortical neurons. Transl Psychiatry. 2019;9(1):1\u201310.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"4192_CR22","doi-asserted-by":"publisher","first-page":"e0150460","DOI":"10.1371\/journal.pone.0150460","volume":"11","author":"H Lee","year":"2016","unstructured":"Lee H, Kang S, Kim W. Drug repositioning for cancer therapy based on large-scale drug-induced transcriptional signatures. PLoS ONE. 2016;11(3):e0150460. https:\/\/doi.org\/10.1371\/journal.pone.0150460.","journal-title":"PLoS ONE"},{"issue":"1","key":"4192_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-021-02540-7","volume":"22","author":"JM Dempster","year":"2021","unstructured":"Dempster JM, Boyle I, Vazquez F, Root DE, Boehm JS, Hahn WC, et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 2021;22(1):1\u201323. https:\/\/doi.org\/10.1186\/s13059-021-02540-7.","journal-title":"Genome Biol"},{"key":"4192_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/227041v1%0A","author":"OM Enache","year":"2017","unstructured":"Enache OM, Lahr DL, Natoli TE, Litichevskiy L, Wadden D, Flynn C, et al. The GCTx format and cmap{Py, R, M} packages: resources for the optimized storage and integrated traversal of dense matrices of data and annotations. bioRxiv. 2017. https:\/\/doi.org\/10.1101\/227041v1%0A.","journal-title":"bioRxiv"},{"issue":"1","key":"4192_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):1\u201313.","journal-title":"Sci Rep"},{"issue":"7","key":"4192_CR26","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","volume":"53","author":"JB Baell","year":"2010","unstructured":"Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53(7):2719\u201340. https:\/\/doi.org\/10.1021\/jm901137j.","journal-title":"J Med Chem"},{"issue":"3","key":"4192_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cmdc.200700139","volume":"3","author":"R Brenk","year":"2008","unstructured":"Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem. 2008;3(3):435\u201344.","journal-title":"ChemMedChem"},{"issue":"24","key":"4192_CR28","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.0.CO;2-U","volume":"38","author":"SJ Teague","year":"1999","unstructured":"Teague SJ, Davis AM, Leeson PD, Oprea T. The design of leadlike combinatorial libraries. Angew Chem Int Ed. 1999;38(24):3743\u20138.","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"4192_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-016-0884-1","volume":"17","author":"L Geistlinger","year":"2016","unstructured":"Geistlinger L, Csaba G, Zimmer R. Bioconductor\u2019s enrichmentbrowser: seamless navigation through combined results of set- & network-based enrichment analysis. BMC Bioinform. 2016;17(1):1\u201311. https:\/\/doi.org\/10.1186\/s12859-016-0884-1.","journal-title":"BMC Bioinform"},{"key":"4192_CR30","unstructured":"Pag\u00e8s H, Carlson M, Falcon S, Maintainer NL. Package \u2018AnnotationDbi.\u2019 Bioconductor Package Maintainer. 2017."},{"key":"4192_CR31","doi-asserted-by":"publisher","DOI":"10.1101\/060012v1%0A","author":"AA Sergushichev","year":"2016","unstructured":"Sergushichev AA. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. bioRxiv. 2016. https:\/\/doi.org\/10.1101\/060012v1%0A.","journal-title":"bioRxiv"},{"issue":"1","key":"4192_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"S Yoon","year":"2021","unstructured":"Yoon S, Baik B, Park T, Nam D. Powerful p-value combination methods to detect incomplete association. Sci Rep. 2021;11(1):1\u201311.","journal-title":"Sci Rep"},{"issue":"1","key":"4192_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-05116-5","volume":"9","author":"F Cheng","year":"2018","unstructured":"Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barab\u00e1si AL, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9(1):1\u201312.","journal-title":"Nat Commun"},{"issue":"7803","key":"4192_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41586-020-2188-x","volume":"580","author":"K Luck","year":"2020","unstructured":"Luck K, Kim DK, Lambourne L, Spirohn K, Begg BE, Bian W, et al. A reference map of the human binary protein interactome. Nature. 2020;580(7803):402\u20138. https:\/\/doi.org\/10.1038\/s41586-020-2188-x.","journal-title":"Nature"},{"issue":"5","key":"4192_CR35","first-page":"1","volume":"1695","author":"G Csardi","year":"2006","unstructured":"Csardi G, Nepusz T. The igraph software package for complex network research. InterJournal. 2006;1695(5):1\u20139.","journal-title":"InterJournal"},{"key":"4192_CR36","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1268\/f1000research.20887.1","volume":"8","author":"JA Gustavsen","year":"2019","unstructured":"Gustavsen JA, Pai S, Isserlin R, Demchak B, Pico AR. RCy3: network biology using cytoscape from within R. Research. 2019;8:1774. https:\/\/doi.org\/10.1268\/f1000research.20887.1.","journal-title":"Research"},{"issue":"1","key":"4192_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms5296","volume":"5","author":"AC Palmer","year":"2014","unstructured":"Palmer AC, Kishony R. Opposing effects of target overexpression reveal drug mechanisms. Nat Commun. 2014;5(1):1\u20138.","journal-title":"Nat Commun"},{"issue":"12","key":"4192_CR38","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49(12):1779\u201384.","journal-title":"Nat Genet"},{"issue":"1","key":"4192_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-91713-2","volume":"11","author":"SK Jaladanki","year":"2021","unstructured":"Jaladanki SK, Elmas A, Malave GS, HuangLin K. Genetic dependency of Alzheimer\u2019s disease-associated genes across cells and tissue types. Sci Rep. 2021;11(1):1\u20138.","journal-title":"Sci Rep"},{"key":"4192_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-3-319-45096-4_6","volume":"13","author":"J M\u00e1rquez","year":"2016","unstructured":"M\u00e1rquez J, Mat\u00e9s JM, Campos-Sandoval JA. Glutaminases. Adv Neurobiol. 2016;13:133\u201371. https:\/\/doi.org\/10.1007\/978-3-319-45096-4_6.","journal-title":"Adv Neurobiol"},{"key":"4192_CR41","first-page":"419","volume":"43","author":"MC Walker","year":"2016","unstructured":"Walker MC, van der Donk WA. The many roles of glutamate in metabolism. Physiol Behav. 2016;43:419\u201330.","journal-title":"Physiol Behav"},{"issue":"1","key":"4192_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/npp.2016.199","volume":"42","author":"E Haroon","year":"2017","unstructured":"Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology. 2017;42(1):193\u2013215.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"4192_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/hmg\/ddy330","volume":"28","author":"L Rumping","year":"2019","unstructured":"Rumping L, Tessadori F, Pouwels PJW, Vringer E, Wijnen JP, Bhogal AA, et al. GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay. Hum Mol Genet. 2019;28(1):96\u2013104.","journal-title":"Hum Mol Genet"},{"key":"4192_CR44","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666110-00015","author":"DM Robinson","year":"2006","unstructured":"Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer\u2019s disease. Drugs. 2006. https:\/\/doi.org\/10.2165\/00003495-200666110-00015.","journal-title":"Drugs"},{"issue":"1","key":"4192_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4192_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov. 2020;6(1):14.","journal-title":"Cell Discov"},{"key":"4192_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.12751","author":"MR Fern\u00e1ndez-Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez-Fern\u00e1ndez MR, Gragera M, Ochoa-Ibarrola L, Quintana-Gallardo L, Valpuesta JM. Hsp70\u2014a master regulator in protein degradation. FEBS Lett. 2017. https:\/\/doi.org\/10.1002\/1873-3468.12751.","journal-title":"FEBS Lett"},{"issue":"1","key":"4192_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.uct.2008.02.001","volume":"3","author":"KR Hande","year":"2008","unstructured":"Hande KR. Topoisomerase II inhibitors. Update Cancer Ther. 2008;3(1):13\u201326.","journal-title":"Update Cancer Ther"},{"issue":"6526","key":"4192_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1126\/science.abb5916","volume":"371","author":"Y Johmura","year":"2021","unstructured":"Johmura Y, Yamanaka T, Omori S, Wang TW, Sugiura Y, Matsumoto M, et al. Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders. Science. 2021;371(6526):265\u201370. https:\/\/doi.org\/10.1126\/science.abb5916.","journal-title":"Science"},{"issue":"February","key":"4192_CR50","first-page":"1","volume":"13","author":"E Sikora","year":"2021","unstructured":"Sikora E, Bielak-Zmijewska A, Dudkowska M, Krzystyniak A, Mosieniak G, Wesierska M, et al. Cellular senescence in brain aging. Front Aging Neurosci. 2021;13(February):1\u201323.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"4192_CR51","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DMI Wilson","year":"2023","unstructured":"Wilson DMI, Cookson MR, Van Den BL, Zetterberg H, Holtzman DM. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693\u2013714. https:\/\/doi.org\/10.1016\/j.cell.2022.12.032.","journal-title":"Cell"},{"issue":"7850","key":"4192_CR52","first-page":"19","volume":"344","author":"JA Driver","year":"2012","unstructured":"Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, et al. Inverse association between cancer and Alzheimer\u2019s disease: results from the Framingham Heart Study. BMJ. 2012;344(7850):19.","journal-title":"BMJ"},{"issue":"12","key":"4192_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pgen.1001257","volume":"6","author":"H Plun-Favreau","year":"2010","unstructured":"Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW. Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet. 2010;6(12):1\u20138.","journal-title":"PLoS Genet"},{"issue":"1","key":"4192_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00831-6","volume":"13","author":"A Ancidoni","year":"2021","unstructured":"Ancidoni A, Bacigalupo I, Remoli G, Lacorte E, Piscopo P, Sarti G, et al. Anticancer drugs repurposed for Alzheimer\u2019s disease: a systematic review. Alzheimer\u2019s Res Ther. 2021;13(1):1\u201315. https:\/\/doi.org\/10.1186\/s13195-021-00831-6.","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"24","key":"4192_CR55","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1111\/bph.12875","volume":"171","author":"W Wrasidlo","year":"2014","unstructured":"Wrasidlo W, Crews LA, Tsigelny IF, Stocking E, Kouznetsova VL, Price D, et al. Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders. Br J Pharmacol. 2014;171(24):5757\u201373. https:\/\/doi.org\/10.1111\/bph.12875.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"4192_CR56","doi-asserted-by":"publisher","first-page":"8920","DOI":"10.1096\/fj.202000564R","volume":"34","author":"M Choudhury","year":"2020","unstructured":"Choudhury M, Yin X, Schaefbauer KJ, Kang JH, Roy B, Kottom TJ, et al. SIRT7-mediated modulation of glutaminase 1 regulates TGF-\u03b2-induced pulmonary fibrosis. FASEB J. 2020;34(7):8920\u201340.","journal-title":"FASEB J"},{"issue":"16","key":"4192_CR57","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1073\/pnas.1001006107","volume":"107","author":"W Hu","year":"2010","unstructured":"Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA. 2010;107(16):7455\u201360. https:\/\/doi.org\/10.1073\/pnas.1001006107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"4192_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-018-1291-5","volume":"10","author":"L Xiang","year":"2019","unstructured":"Xiang L, Mou J, Shao B, Wei Y, Liang H, Takano N, et al. Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization. Cell Death Dis. 2019;10(2):1\u201315.","journal-title":"Cell Death Dis"},{"key":"4192_CR59","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666190416165004","author":"JM Mat\u00e9s","year":"2019","unstructured":"Mat\u00e9s JM, Campos-sandoval JA, Santos-jim\u00e9nez JDL, Segura JA, Alonso FJ, M\u00e1rquez J. Metabolic reprogramming of cancer by chemicals that target glutaminase metabolic reprogramming of cancer by chemicals that target glutaminase isoenzymes. Curr Med Chem. 2019. https:\/\/doi.org\/10.2174\/0929867326666190416165004.","journal-title":"Curr Med Chem"},{"issue":"12","key":"4192_CR60","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/ene.13748","volume":"25","author":"N Chartier","year":"2018","unstructured":"Chartier N, Epstein J, Soudant M, Dahan C, Michaud M, Pittion-Vouyovitch S, et al. Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study. Eur J Neurol. 2018;25(12):1439\u201345.","journal-title":"Eur J Neurol"},{"key":"4192_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17030290","author":"IC Lee","year":"2016","unstructured":"Lee IC, Choi BY. Withaferin-A\u2014a natural anticancer agent with pleitropic mechanisms of action. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17030290.","journal-title":"Int J Mol Sci"},{"key":"4192_CR62","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nrd3600","volume":"10","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov. 2011;10:897\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"4192_CR63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1100\/tsw.2010.49","volume":"10","author":"SK Sharma","year":"2010","unstructured":"Sharma SK. Hepatocyte growth factor in synaptic plasticity and Alzheimer \u2019 s disease. Sci World J. 2010;10:457\u201361.","journal-title":"Sci World J"},{"issue":"237","key":"4192_CR64","doi-asserted-by":"publisher","first-page":"108171","DOI":"10.1016\/j.pharmthera.2022.108171","volume":"1","author":"M Eshraghi","year":"2022","unstructured":"Eshraghi M, Ahmadi M, Afshar S, Lorzadeh S, Adlimoghaddam A, Rezvani Jalal N, et al. Enhancing autophagy in Alzheimer\u2019s disease through drug repositioning. Pharmacol Ther. 2022;1(237):108171.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"4192_CR65","doi-asserted-by":"publisher","first-page":"628","DOI":"10.14336\/AD.2017.0103","volume":"8","author":"JR Aunan","year":"2017","unstructured":"Aunan JR, Cho WC, S\u00f8reide K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks. Aging Dis. 2017;8(5):628\u201342.","journal-title":"Aging Dis"},{"key":"4192_CR66","unstructured":"Imre G. Anti-apoptotic and Pro-inflammatory Signaling in Cancer Cells\u202f: Status and Modulation by Chemotherapeutic Drugs. 2007. https:\/\/kops.uni-konstanz.de\/server\/api\/core\/bitstreams\/81bf6357-fe5e-4343-a8da-c93a8224f505\/content."},{"issue":"2","key":"4192_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22020888","volume":"22","author":"S Yamamoto","year":"2021","unstructured":"Yamamoto S, Egashira N. Pathological mechanisms of bortezomib-induced peripheral neuropathy. Int J Mol Sci. 2021;22(2):1\u201314.","journal-title":"Int J Mol Sci"},{"key":"4192_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/S1871-5125(10)35005-9","volume-title":"Parbendazole","author":"BMH Al-Hadiya","year":"2010","unstructured":"Al-Hadiya BMH. Parbendazole. Cambridge: Academic Press; 2010."},{"issue":"65","key":"4192_CR69","doi-asserted-by":"publisher","first-page":"103276","DOI":"10.1016\/j.ebiom.2021.103276","volume":"1","author":"A Manousi","year":"2021","unstructured":"Manousi A, G\u00f6ttle P, Reiche L, Cui QL, Healy LM, Akkermann R, et al. Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence. EBioMedicine. 2021;1(65):103276.","journal-title":"EBioMedicine"},{"key":"4192_CR70","doi-asserted-by":"publisher","DOI":"10.2174\/1871527316666170124165222","author":"L Dezsi","year":"2017","unstructured":"Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets. 2017. https:\/\/doi.org\/10.2174\/1871527316666170124165222.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"4192_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00340","author":"JPM Finberg","year":"2016","unstructured":"Finberg JPM, Rabey JM. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol. 2016. https:\/\/doi.org\/10.3389\/fphar.2016.00340.","journal-title":"Front Pharmacol"},{"issue":"12","key":"4192_CR72","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fncir.2018.00113","volume":"18","author":"LE Trudeau","year":"2018","unstructured":"Trudeau LE, El Mestikawy S. Glutamate cotransmission in cholinergic, GABAergic and monoamine systems: contrasts and commonalities. Front Neural Circuits. 2018;18(12):113.","journal-title":"Front Neural Circuits"},{"issue":"5","key":"4192_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics14050987","volume":"14","author":"RI Teleanu","year":"2022","unstructured":"Teleanu RI, Preda MD, Niculescu AG, Vlad\u00e2cenco O, Radu CI, Grumezescu AM, et al. Current strategies to enhance delivery of drugs across the blood-brain barrier. Pharmaceutics. 2022;14(5):1\u201330.","journal-title":"Pharmaceutics"},{"issue":"2","key":"4192_CR74","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2165\/00003088-199631020-00004","volume":"31","author":"E Yukawa","year":"1996","unstructured":"Yukawa E. Optimisation of antiepileptic drug therapy. Clin Pharmacokinet. 1996;31(2):120\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4192_CR75","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/1535-7163.MCT-11-0634","volume":"11","author":"F Meng","year":"2012","unstructured":"Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther. 2012;11(3):740\u201351.","journal-title":"Mol Cancer Ther"},{"key":"4192_CR76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2478\/tumor-2013-0003","volume":"1","author":"KE Lindquist","year":"2013","unstructured":"Lindquist KE, Cran JD, Kordic K, Chua PC, Winters GC, Tan JS, et al. Selective radiosensitization of hypoxic cells using BCCA621C: a novel hypoxia activated prodrug targeting DNA-dependent protein kinase. Tumor Microenviron Ther. 2013;1:46\u201355.","journal-title":"Tumor Microenviron Ther"},{"issue":"11","key":"4192_CR77","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959\u201372. https:\/\/doi.org\/10.1038\/jcbfm.2012.126.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4192_CR78","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.eplepsyres.2018.06.003","volume":"145","author":"JJ Luszczki","year":"2018","unstructured":"Luszczki JJ, Mazurkiewicz LP, Wroblewska-Luczka P, Wlaz A, Ossowska G, Szpringer M, et al. Combination of phenobarbital with phenytoin and pregabalin produces synergy in the mouse tonic-clonic seizure model: an isobolographic analysis. Epilepsy Res. 2018;145:116\u201322. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.06.003.","journal-title":"Epilepsy Res"},{"key":"4192_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25010014","author":"B Juraszek","year":"2020","unstructured":"Juraszek B, Na\u0142\u0105ecz KA. SLC22A5 (OCTN2) carnitine transporter-indispensable for cell metabolism, a jekyll and hyde of human cancer. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25010014.","journal-title":"Molecules"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04192-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04192-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04192-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T06:06:50Z","timestamp":1684562810000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04192-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4192"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04192-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,20]]},"assertion":[{"value":"26 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AM and SS are co-founders of Bash Biotech Inc, USA and XL is employed by Bash Biotech Inc, USA. The other authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}